From fertility breakthroughs to AI diagnostics: reflecting on the top 10 innovations in women’s health in 2025

While 2025 was widely described as a turning point for women’s health, the progress was driven not by abstract trends but by concrete technologies, trials and policy changes. Below are specific, verifiable examples behind each of the ten key innovation areas that shaped the year.

1. IVF without heavy hormone stimulation

Example: Gameto’s Fertilo In 2025, biotech company Gameto advanced clinical trials of Fertilo, a stem-cell-derived ovarian support cell platform that matures eggs outside the body. The approach significantly reduces hormone injections and has already resulted in live births overseas, with pivotal trials under way ahead of potential regulatory approval.

2. In-vitro gametogenesis moves beyond theory

Example: OHSU skin-cell-derived egg research Researchers at Oregon Health & Science University, led by Prof Shoukhrat Mitalipov, demonstrated that human skin cells could be reprogrammed into egg-like cells capable of fertilisation to the early embryo stage in laboratory conditions. Although not viable for implantation, the work marked a major step forward in IVG science.

3. Artificial womb technology refined

Example: CHOP’s EXTEND system The EXTEND artificial womb, developed at the Children’s Hospital of Philadelphia, showed improved stability and neurological outcomes in preclinical lamb studies equivalent to 23–24-week human gestation. In 2025, researchers focused on infection control and circulation refinement ahead of future regulatory review.

4. Endometriosis drug development progresses

Example: Linzagolix (Yselty) expansion The oral GnRH antagonist linzagolix continued expansion into new markets in 2025, offering a hormone-modulating treatment with adjustable dosing. Alongside it, multiple non-hormonal candidates targeting inflammation and nerve pain entered Phase II trials, addressing a long-standing gap in endometriosis care.

5. Non-hormonal menopause treatments reach patients

Example: Fezolinetant (Veozah) In 2025, fezolinetant, a neurokinin-3 receptor antagonist, became more widely prescribed in Europe following regulatory approval, offering relief from hot flushes without using oestrogen — a major option for women who cannot take HRT.

6. AI integrated into breast cancer screening

Example: Google Health and NHS AI trials NHS breast screening trials using AI decision-support systems, including tools developed with Google Health, reported improved cancer detection rates with no increase in false positives when AI was used alongside radiologists, supporting gradual clinical rollout.

7. Safer, less invasive fibroid and gynaecological surgery

Example: Sonata and Acessa systems The Sonata transcervical fibroid ablation system and Acessa radiofrequency ablation gained wider uptake in 2025, allowing fibroids to be treated without hysterectomy or major surgery — preserving fertility and reducing recovery time.

8. Home monitoring transforms maternal care

Example: Blood pressure monitoring for pre-eclampsia NHS trusts expanded use of remote blood pressure monitoring platforms for pregnant women at risk of pre-eclampsia, following evidence that home monitoring reduced emergency admissions and improved early intervention.

9. Addressing gender bias in pain treatment

Example: NICE guideline updates and clinician training In 2025, updated NICE guidance and medical school curricula explicitly addressed sex-based differences in pain perception and treatment, particularly in conditions such as migraine, pelvic pain and autoimmune disease, responding to growing evidence of systemic bias.

10. Targeted funding for women’s health research

Example: UK Women’s Health Strategy funding streams The UK government expanded ring-fenced funding for women’s health research, supporting projects focused on menstrual health, menopause, pregnancy loss and gynaecological cancers — helping move these areas out of chronic underfunding.

From promise to practice

Taken together, these examples show that 2025 was not defined by a single breakthrough, but by incremental, practical advances — many of them long overdue. While most remain at different stages of validation and access, they collectively signalled a structural shift: women’s health innovation is no longer niche, but increasingly central to modern medicine.